Track topics on Twitter Track topics that are important to you
Viva Biotech, a Shanghai CRO that includes partnering as part of its business plan, will seek to raise $194 million in a Hong Kong IPO that values the company at $750 million. Viva is a structure-based, integrated drug discovery CRO. For selected clients, Viva offers a Equity for Services model that provides clients about $1.5 million in either cash or services in return for equity. Viva expects to hold half the equity for about 2.5 years and the rest for 5.5 years. So far, it has earned returns of between 200% and 500% on five closed investments. More details....
Share this with colleagues:
Original Article: Viva Biotech Raising $194 Million in Hong Kong IPO for CRO OperationsNEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...